178 related articles for article (PubMed ID: 33193460)
1. Editorial: Immunogenicity of Proteins Used as Therapeutics.
Sauna ZE; Richards SM; Maillere B; Jury EC; Rosenberg AS
Front Immunol; 2020; 11():614856. PubMed ID: 33193460
[No Abstract] [Full Text] [Related]
2. Successful desensitization of elosulfase alfa-induced anaphylaxis in a pediatric patient with Morquio syndrome.
Guvenir H; Dibek Misirlioglu E; Capanoglu M; Buyuktiryaki B; Unal O; Toyran M; Kocabas CN
J Allergy Clin Immunol Pract; 2017; 5(4):1156-1157. PubMed ID: 28689831
[No Abstract] [Full Text] [Related]
3. Immunogenicity in Protein and Peptide Based-Therapeutics: An Overview.
Fernandez L; Bustos RH; Zapata C; Garcia J; Jauregui E; Ashraf GM
Curr Protein Pept Sci; 2018; 19(10):958-971. PubMed ID: 28847291
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity of protein therapeutics.
De Groot AS; Scott DW
Trends Immunol; 2007 Nov; 28(11):482-90. PubMed ID: 17964218
[TBL] [Abstract][Full Text] [Related]
5. Determinants of immunogenic response to protein therapeutics.
Singh SK; Cousens LP; Alvarez D; Mahajan PB
Biologicals; 2012 Sep; 40(5):364-8. PubMed ID: 22770604
[TBL] [Abstract][Full Text] [Related]
6. Development of antibody surrogates for the treatment of cancers and autoimmune disease.
Kodadek T
Curr Opin Chem Biol; 2010 Dec; 14(6):721-7. PubMed ID: 20674470
[TBL] [Abstract][Full Text] [Related]
7. Autoimmune therapies targeting costimulation and emerging trends in multivalent therapeutics.
Chittasupho C; Siahaan TJ; Vines CM; Berkland C
Ther Deliv; 2011 Jul; 2(7):873-89. PubMed ID: 21984960
[TBL] [Abstract][Full Text] [Related]
8. Tipping the balance towards tolerance: the basis for therapeutic immune modulation by gold?
Carey JB; Carey MA; Allshire A; van Pelt FN
Autoimmunity; 2005 Sep; 38(6):393-7. PubMed ID: 16278143
[TBL] [Abstract][Full Text] [Related]
9. Antibody therapeutics targeting ion channels: are we there yet?
Sun H; Li M
Acta Pharmacol Sin; 2013 Feb; 34(2):199-204. PubMed ID: 23381110
[TBL] [Abstract][Full Text] [Related]
10. Successful sebelipase alfa desensitization in a pediatric patient.
Kulhas Celik I; Kucukcongar Yavas A; Unal Uzun O; Siyah Bilgin B; Dibek Misirlioglu E; Gunduz M
J Allergy Clin Immunol Pract; 2019 Feb; 7(2):732-733. PubMed ID: 30053591
[No Abstract] [Full Text] [Related]
11. Immuno-PCR assays for immunogenicity testing.
Spengler M; Adler M; Jonas A; Niemeyer CM
Biochem Biophys Res Commun; 2009 Sep; 387(2):278-82. PubMed ID: 19577544
[TBL] [Abstract][Full Text] [Related]
12. Minimizing the immunogenicity of protein therapeutics.
Chirino AJ; Ary ML; Marshall SA
Drug Discov Today; 2004 Jan; 9(2):82-90. PubMed ID: 15012932
[TBL] [Abstract][Full Text] [Related]
13. Rehabilitation or the death penalty: autoimmune B cells in the dock.
Dahal LN; Cragg MS
Eur J Immunol; 2015 Mar; 45(3):687-91. PubMed ID: 25639261
[TBL] [Abstract][Full Text] [Related]
14. Challenges and Opportunities for the Subcutaneous Delivery of Therapeutic Proteins.
Turner MR; Balu-Iyer SV
J Pharm Sci; 2018 May; 107(5):1247-1260. PubMed ID: 29336981
[TBL] [Abstract][Full Text] [Related]
15. Recent Advances in Assessing Immunogenicity of Therapeutic Proteins: Impact on Biotherapeutic Development.
Lu Y; Khawli LA; Purushothama S; Theil FP; Partridge MA
J Immunol Res; 2016; 2016():8141269. PubMed ID: 27642612
[No Abstract] [Full Text] [Related]
16. Benefits of Prophylactic Short-Course Immune Tolerance Induction in Patients With Infantile Pompe Disease: Demonstration of Long-Term Safety and Efficacy in an Expanded Cohort.
Desai AK; Baloh CH; Sleasman JW; Rosenberg AS; Kishnani PS
Front Immunol; 2020; 11():1727. PubMed ID: 32849613
[TBL] [Abstract][Full Text] [Related]
17. A role for plasma cell targeting agents in immune tolerance induction in autoimmune disease and antibody responses to therapeutic proteins.
Rosenberg AS; Pariser AR; Diamond B; Yao L; Turka LA; Lacana E; Kishnani PS
Clin Immunol; 2016 Apr; 165():55-9. PubMed ID: 26928739
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and autoimmunity during anti-TNF therapy.
Atzeni F; Talotta R; Salaffi F; Cassinotti A; Varisco V; Battellino M; Ardizzone S; Pace F; Sarzi-Puttini P
Autoimmun Rev; 2013 May; 12(7):703-8. PubMed ID: 23207283
[TBL] [Abstract][Full Text] [Related]
19. Biotherapies targeting T and B cells: from immune suppression to immune tolerance.
Chatenoud L
Curr Opin Pharmacol; 2015 Aug; 23():92-7. PubMed ID: 26099946
[TBL] [Abstract][Full Text] [Related]
20. Takeda's second bet on DARTs.
Nat Biotechnol; 2014 Nov; 32(11):1070. PubMed ID: 25380421
[No Abstract] [Full Text] [Related]
[Next] [New Search]
